mfn-cus-featured-news

Nanologica’s Annual Report 2022 Published

24 March, 2023

Nanologica AB’s annual report for 2022 is now published on the company’s website. The annual report in Swedish, and an English translation, is available on www.nanologica.com as a pdf. The annual report in Swedish is also available in the European Single Electronic Format (ESEF). Swedish: https://nanologica.com/category/finansiella-rapporter/ English translation: https://nanologica.com/category/financial-reports/ For further information, please contact: Johanna Johansson, Director IR, Communications and Marketing Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com This information is information that

Nanologica’s Interim Report Jan-Sep 2022

11 November, 2022

Report presentation Q3 2022 FINANCIAL SUMMARY Net sales for the third quarter amounted to TSEK 401 (2,119) and for the nine-month period to TSEK 881 (12,238) The operating result for the quarter amounted to TSEK -9,610 (-11,718) and for the nine-month period to TSEK -37,599 (-26,581) Result after tax for the quarter amounted to TSEK -10,988 (-12,546) and for the nine-month period to TSEK -40,376 (-29,607) Earnings per share before and after dilution were

Nanologica Raises MSEK 79,8 in Rights Issue

10 October, 2022

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Nanologica AB (publ) (”Nanologica" or the "Company") today announces the outcome of the new shares issue with preferential rights for Nanologica's existing shareholders (the

Nanologica Receives Order for Silica for Preparative Chromatography from US Customer

3 October, 2022

Nanologica AB (publ) has received an order for the company's silica for preparative chromatography to a value of approximately TSEK 230. The order comes from a customer in the North American market. During 2022, Nanologica has completed the up-scaling to large-scale production of the company’s commercial silica for preparative chromatography, NLAB Saga®. This order is a direct consequence of the company now being able to deliver the volumes of silica required for customers to be

Nanologica Publishes Prospectus in Connection with Preferential Rights Issue

20 September, 2022

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The Board of Directors of Nanologica AB (publ) ("Nanologica" or the Company") announced on 23 August 2022 that the Board of Directors has resolved

Nanologica Receives Order for Silica for Preparative Chromatography

31 August, 2022

Nanologica AB (publ) has taken an order for the company's silica for preparative chromatography at a value of approximately MSEK 1.3. The order comes from Nanologica's partner in China, Yunbo Technology (Beijing) Co. Ltd. In July 2019, Nanologica signed an agreement with Chinese Yunbo Technology for the supply of silica for preparative chromatography worth approximately MUSD 14 (currently equivalent to approximately MSEK 150), between 2021 and 2026. The order that has now been placed is

About us

Nanologica is a Swedish nanotechnology company, world-leading in the development of nanoporous silica particles for purification by chromatography. A proprietary production method enables the company to create supreme products by precisely controlling the shape, size, porosity, and surface properties of silica particles. Nanologica provides products of high-quality silica used in the purification of peptide drugs. These products can contribute to lower costs and higher production for pharmaceutical manufacturers, which increases the availability of cost-effective medicines and gives more people around the world access to vital treatment for diabetes and obesity. Nanologica is headquartered in Södertälje and Nanologica’s share (NICA) is listed on Nasdaq Stockholm Main Market.